5-ASA in ulcerative colitis: Improving treatment compliance

World Journal of Gastroenterology

Volumn 15, Issue 35, 2009, Pages 4353-4355

  Prantera, Cosimo ^a   Rizzi, Marina ^b  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

5 aminosalicylic acid; Mesalamine; Multi matrix; Patient compliance; Ulcerative colitis

Indexed keywords

MESALAZINE; PLACEBO; SALAZOSULFAPYRIDINE; SALICYLIC ACID DERIVATIVE;

BEDTIME DOSAGE; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; DOSAGE SCHEDULE COMPARISON; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG EFFICACY; HUMAN; MAINTENANCE THERAPY; PATIENT COMPLIANCE; REMISSION; REVIEW; ULCERATIVE COLITIS;

EID: 72049085802     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.15.4353     Document Type: Review

References (15)

1. Bitton A. Medical management of ulcerative proctitis, proctosigmoiditis, and left-sided colitis. Semin Gastrointest Dis 2001; 12: 263-274 (Pubitemid 33027470)
2. Farmer RG, Easley KA, Rankin GB. Clinical patterns, natural history, and progression of ulcerative colitis. A long-term follow-up of 1116 patients. Dig Dis Sci 1993; 38: 1137-1146
3. Safdi M, DeMicco M, Sninsky C, Banks P, Wruble L, Deren J, Koval G, Nichols T, Targan S, Fleishman C, Wiita B. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 1997; 92: 1867-1871 (Pubitemid 27440908)
4. Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003; 114: 39-43 (Pubitemid 36126514)
5. Prantera C, Viscido A, Biancone L, Francavilla A, Giglio L, Campieri M. A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. Inflamm Bowel Dis 2005; 11: 421-427 (Pubitemid 40704075)
6. Tenjarla S, Romasanta V, Zeijdner E, Villa R, Moro L. Release of 5-aminosalicylate from an MMX mesalamine tablet during transit through a simulated gastrointestinal tract system. Adv Ther 2007; 24: 826-840 (Pubitemid 351612256)
7. D'Haens G, Hommes D, Engels L, Baert F, van der Waaij L, Connor P, Ramage J, Dewit O, Palmen M, Stephenson D, Joseph R. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study. Aliment Pharmacol Ther 2006; 24: 1087-1097 (Pubitemid 44386534)
8. Brunner M, Assandri R, Kletter K, Tschurlovits M, Corrado ME, Villa R, Eichler HG, Muller M. Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation. Aliment Pharmacol Ther 2003; 17: 395-402 (Pubitemid 36259402)
9. Lichtenstein GR, Kamm MA, Boddu P, Gubergrits N, Lyne A, Butler T, Lees K, Joseph RE, Sandborn WJ. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2007; 5: 95-102 (Pubitemid 46096842)
10. Kamm MA, Sandborn WJ, Gassull M, Schreiber S, Jackowski L, Butler T, Lyne A, Stephenson D, Palmen M, Joseph RE. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007; 132: 66-75; quiz 432-433
11. Kamm MA, Lichtenstein GR, Sandborn WJ, Schreiber S, Lees K, Barrett K, Joseph R. Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis. Inflamm Bowel Dis 2009; 15: 1-8
12. Prantera C, Kohn A, Campieri M. Once daily MMx® 5 Aminosalicylic acid versus twice-daily Asacol® for the maintenance of remission of ulcerative colitis: a preliminary analysis. Gastroenterology 2008; 134: A492 (Abstract T1136)
13. Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18: 191-198 (Pubitemid 36951655)
14. Levy RL, Feld AD. Increasing patient adherence to gastroenterology treatment and prevention regimens. Am J Gastroenterol 1999; 94: 1733-1742
15. Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2003; CD000543